Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

PURPOSE: We previously reported a 44% overall response rate (ORR) with the oral BCL-2 inhibitor venetoclax in a phase I study of relapsed/refractory non–Hodgkin lymphoma (NHL). Complete response (CR) was observed in patients with mantle cell lymphoma [(MCL), 21%, n = 6/28] and follicular lymphoma [(...

Descripción completa

Detalles Bibliográficos
Autores principales: Davids, Matthew S., Roberts, Andrew W., Kenkre, Vaishalee P., Wierda, William G., Kumar, Abhijeet, Kipps, Thomas J., Boyer, Michelle, Salem, Ahmed Hamed, Pesko, John C., Arzt, Jennifer A., Mantas, Margaret, Kim, Su Y., Seymour, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Research Briefs: Clinical Trial Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401543/
https://www.ncbi.nlm.nih.gov/pubmed/34083230
http://dx.doi.org/10.1158/1078-0432.CCR-20-4842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401543/
https://www.ncbi.nlm.nih.gov/pubmed/34083230
http://dx.doi.org/10.1158/1078-0432.CCR-20-4842

Ejemplares similares